A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

3.3K views

⸱

DOI:

10.3791/64288

⸱

August 17th, 2022

 ,  ,  ,  ,  ,  ,  ,  ,  ,  , 

* These authors contributed equally

In This Article

Summary

A self-assembled peptide-poloxamine nanoparticle (PP-sNp) is developed using a microfluidic mixing device to encapsulate and deliver in vitro transcribed messenger RNA. The described mRNA/PP-sNp could efficiently transfect cultured cells in vitro.

Abstract

In vitro transcribed messenger RNA (mRNA) vaccines have displayed enormous potential in fighting against the coronavirus disease 2019 (COVID-19) pandemic. Efficient and safe delivery systems must be included in the mRNA vaccines due to the fragile properties of mRNA. A self-assembled peptide-poloxamine nanoparticle (PP-sNp) gene delivery system is specifically designed for the pulmonary delivery of nucleic acids and displays promising capabilities in mediating successful mRNA transfection. Here, an improved method for preparing PP-sNp is described to elaborate on how the PP-sNp encapsulates Metridia luciferase (MetLuc) mRNA and successfully transfects cultured cells. MetLuc-mRNA is obtained by an in vitro transcription process from a linear DNA template. A PP-sNp is produced by mixing synthetic peptide/poloxamine with mRNA solution using a microfluidic mixer, allowing for the self-assembly of PP-sNp. The charge of PP-sNp is subsequently evaluated by measuring the zeta potential. Meanwhile, the polydispersity and hydrodynamic size of PP-sNp nanoparticles are measured using dynamic light scattering. The mRNA/PP-sNp nanoparticles are transfected into cultured cells, and supernatants from the cell culture are assayed for luciferase activity. The representative results demonstrate their capacity for in vitro transfection. This protocol may shed light on developing next-generation mRNA vaccine delivery systems.

Introduction

Vaccination has been heralded as one of the most efficient medical interventions for reducing the morbidity and mortality caused by infectious diseases1. The importance of vaccines has been demonstrated since the outbreak of coronavirus disease 2019 (COVID-19). As opposed to the traditional concept of injecting inactivated or live-attenuated pathogens, state-of-the-art vaccine approaches, such as nucleic acid-based vaccines, concentrate on preserving the immune-stimulatory properties of the target pathogens while avoiding the potential safety issues associated with the conventional whole-microbial virus- or in bacteria-based vaccines. Both DNA-....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. In vitro transcription of chemically modified mRNA

NOTE: It is required to use nuclease-free tubes, reagents, glassware, pipette tips, etc., because RNases are ubiquitous in the environment, such as laboratory solutions, instrument surfaces, hair, skin, dust, etc. Clean the bench surfaces and pipettes thoroughly before use, and wear gloves to avoid RNase contamination.

  1. Perform linearization of the DNA template.
    1. Synthesize the open reading frame (ORF) of Metridia luciferase (MetLuc) flanked by a T7 polymerase promoter, 5' untranslated region (UTR), 3'UTR, and poly (A) tails and clo....

Access restricted. Please log in or start a trial to view this content.

Results

The recombinant plasmid was digested to produce the linearized DNA template (Figure 2A). Using the protocol described, The T7 in vitro transcription kit can produce up to 80-120 µg of uncapped MetLuc-mRNA per 20 µL reaction and 50-60 µg of capped MetLuc-mRNA per 100 µL reaction. When analyzed with electrophoresis, intact MetLuc-mRNA with high quality should show a single and clear band, as displayed in Figure 2B. Contaminants introduced into the reactio.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The protocol described here not only allows the cost-effective and rapid production of IVT mRNA vaccine formulations with defined properties, but it also offers the possibility to customize the PP-sNp formulation according to specific therapeutic purposes, such as gene therapy. In order to ensure the successful generation of IVT mRNA/PP-sNp, it is suggested to pay extra attention to some critical steps. When working with mRNA, always remember that RNase-free conditions should be maintained throughout the process because .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (NSFC, Grant No. 82041045 and 82173764), the major project of Study on Pathogenesis and Epidemic Prevention Technology System (2021YFC2302500) by the Ministry of Science and Technology of China, the Chongqing Talents: Exceptional Young Talents Project (CQYC202005027), and the Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0136). The authors are grateful to Dr. Xiaoyan Ding for measuring the hydrodynamic diameter (nm) and polydispersity index (PDI).

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
BamHITakara1010
cap 1 capping systemJinanM082
Dendritic cell-lineSigmaSCC142
DNA sequenceGenescript
Human bronchial epithelial cellsSigmaSCC150
KpnITakara1068
LPBeyotimeC0533
Lithium chlorideAPEXBioB6083
Malvern Zetasizer Nano ZS90MalvernNB007605
Microfluidic chipZHONGXINQIHENGStandard PDMS chip
Microplate readersThermoFisherVarioskan lux
NanoDrop OneThermoFisherND-ONE-W (A30221)
Nuclease-free waterThermoFisherAM9932
OptiMEMGibco31985070
Penicillin-streptomycinGibco15140122
PseudouridineAPE×BioB7972
QIAprep Spin Miniprep KitQiagen27106
Quanti-LucInvivoGenRep-qlc2
RiboRuler High Range RNA LadderThermoFisherSM1821
RNase-free conical tubeBiosharpBS-100-M
RPMI Medium 1640ThermoFisherC11875500BT
Syringe pumpChemyxFusion 101
T7 transcription KitJinanE131

References

  1. Fehervari, Z., Minton, K., Duarte, J. H. Nature milestones in vaccines. Springer Nature. , Available from: https://www.nature.com/collections/hcajdiajij (2020).
  2. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology. 40 (6), 840-854 (2022).
  3. Mulligan, M. J., et al.....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

mRNA TransfectionIn Vitro TranscriptionPulmonary mRNA DeliveryMetridia Luciferase mRNAMicrofluidic MixingDynamic Light ScatteringHuman Bronchial CellsTransmission Electron MicroscopymRNA Vaccine Delivery